Comanagement of TNFI-induced psoriasis in rheumatology and dermatology means better patient outcomes, according to a decade of experience at Cleveland Clinic.
This is the first reported case in which an HIV-positive patient with both severe psoriasis and KS is treated with ustekinumab. The results suggest that the biologic may be a safe and effective treatment for these patients.
A recent Cleveland Clinic study determined that paraoxonase-1 (PON1) has the potential for use as a biomarker for cardiac risk in psoriatic disease.
The Husni research lab combines clinical savvy with biochemical and molecular biology expertise to home in on the molecular basis of immune-mediated diseases. An early focus: selective TNF-α receptor inhibition.